Aquestive Therapeutics(NASDAQ) AQST

Aquestive makes thin, dissolvable strips that deliver medicine through the mouth instead of using needles. These products help people with severe allergies and brain disorders get treatment more easily. The technology replaces painful injections or bulky devices with a simple film the size of a stamp.

The Product Portfolio

• PharmFilm Technology: Thin strips placed under the tongue or in the cheek that dissolve to release medication; avoids the liver's first-pass effect for faster absorption.
• Licensed Medicines: Commercial products for opioid dependence, seizures, and nausea; generated $44.5 million in total revenue during 2025.
• Anaphylm: An experimental film for severe allergic reactions; designed as a needle-free alternative to standard auto-injectors like EpiPen.
• Libervant: A buccal film for managing sudden seizure clusters in epilepsy patients; currently holds tentative approval status in the U.S.
• AdrenaVerse Platform: A library of over 20 experimental products using epinephrine to treat various immune and skin conditions.

Strategic Moves and Partnerships

• Licensed global rights for Sympazan to Otter Pharmaceuticals, a subsidiary of Assertio Holdings, in October 2022 for $9 million.
• Expanded a deal with Pharmanovia in March 2023 to market Libervant in most regions outside the U.S., Canada, and China.
• Terminated development and supply agreements with MTPA and Haisco in June 2024 to consolidate its focus.
• Sold future royalty rights for the Parkinson's drug KYNMOBI to Sunovion under a monetization agreement originally signed in 2020.

What Makes These Strips Different?

Aquestive leads the world in prescription oral film manufacturing and has shipped more than two billion doses. Its technology helps patients with swallowing difficulties or needle phobias receive necessary medicine safely and quickly.

Checking the Vitals

• Revenue reached $13 million in Q4 2025, up 9.7% from $11.9 million in Q4 2024.
• Net income was -$31.9 million in Q4 2025, a loss that deepened 86.8% from -$17.1 million the prior year.
• Operating income hit -$28.8 million in Q4 2025, worsening 112.4% from -$13.6 million in Q4 2024.
• Free cash flow was -$8.6 million in Q4 2025, a deficit that deepened 31.5% compared to -$6.5 million in Q4 2024.

The Road Ahead

Aquestive has transitioned from a manufacturing partner for other firms into a developer of its own complex drug treatments. While it faces regulatory hurdles and widening losses, its core film technology remains a unique alternative to traditional medical injections.